ALVO vs AMRX vs AMPH Stock Comparison

Alvotech, Amneal Pharmaceuticals and Amphastar Pharmaceuticals Prices as of Nov 13, 2026 Peers: Industry group
ALVO Alvotech
$4.19 -19.0% 1M -24.1% 1Y
Market cap
$1.28B
P/E
–
Revenue (TTM)
-$131.44M
Div. yield
–
Generic Drugs Healthcare

Head to Head

11 decided of 12

Amneal Pharmaceuticals leads on 7 of the 12 questions below (Amneal Pharmaceuticals 7, Amphastar Pharmaceuticals 4). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionALVOAMRXAMPHLeader
Larger companyMarket capitalisation $1.28B $7.15B $1.28B AMRX
Cheaper on earningsLower P/E, profitable companies only -41.3x 53.6x 12.9x AMPH
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 21.4x 8.8x AMPH
Faster revenue growthRevenue growth, trailing twelve months -137.5% +8.9% +3.1% AMRX
More profitableNet margin, trailing twelve months — 4.2% 13.3% AMPH
Better return on capitalReturn on invested capital 8.2% 14.3% 7.6% AMRX
Less leveragedLower net debt / EBITDA 4.6x 4.3x 7.5x AMRX
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months -24.1% +85.6% +11.4% AMRX
Better 5-year returnAnnualised price return, 5 years -15.8%/yr +32.7%/yr +6.6%/yr AMRX
Less volatileAnnualised volatility, 1 year 70.5% 34.3% 53.3% AMRX
Higher overall scoreMean of the five percentile scores vs peers 66/100 69/100 72/100 AMPH

Percentile Scorecard

ALVOAMRXAMPH

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisALVOAMRXAMPH
Valuation 94 #41 of 660 90 #69 of 660 98 #13 of 660
Growth 79 #132 of 619 70 #189 of 619 41 #366 of 619
Profitability 71 #172 of 595 87 #80 of 595 87 #78 of 595
Financial Health 22 #536 of 683 11 #606 of 683 35 #443 of 683
Shareholder Returns – 89 #53 of 459 98 #12 of 459
Overall 66 69 72
  • ALVO ranked among 695 companies in Pharmaceuticals and Biotechnology
  • AMRX ranked among 695 companies in Pharmaceuticals and Biotechnology
  • AMPH ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodALVOAMRXAMPHSPY
1 month -19.0%+13.1%+12.6% -2.0%
3 months +3.5%+17.8%+40.5% -2.8%
6 months +26.6%+79.2%+74.1% +2.0%
Year to date -18.3%+69.7%+9.7% +10.6%
1 year -24.1%+85.6%+11.4% +12.2%
3 years -53.4%+367.8%-47.8% +68.1%
3 years, per year -22.5%+67.3%-19.5% +18.9%
5 years -57.7%+310.4%+37.9% +61.4%
5 years, per year -15.8%+32.7%+6.6% +10.1%
10 years ——+40.3% +248.5%
10 years, per year ——+3.4% +13.3%

Risk

MeasureALVOAMRXAMPHSPY
Volatility, 1Y 70.5%34.3%53.3% 13.6%
Downside volatility, 1Y 65.0%30.7%66.0% 13.9%
Beta vs S&P 500, 1Y 0.840.670.43 1.00
Return / volatility, 1Y -0.342.490.21 0.90
Max drawdown, 5Y -82.6%-75.4%-74.0% -25.4%
From 52-week high -31.9%-1.5%-0.1% -3.2%
52-week high $6.15$21.71$29.40 $779.14
52-week low $3.00$11.52$16.87 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleALVOAMRXAMPH
P/E now vs peer median -39.2xmedian 17.0x 53.8xmedian 17.0x 12.6xmedian 17.0x
P/S now vs peer median -9.9xmedian 8.4x 2.3xmedian 8.4x 1.7xmedian 8.4x
EV/EBITDA now vs peer median 9.5xmedian 14.6x 15.1xmedian 14.6x 32.2xmedian 14.6x
P/FCF now vs peer median -10.7xmedian 19.0x 193.9xmedian 19.0x 9.0xmedian 19.0x
P/B now vs peer median -4.6xmedian 2.0x 14.0xmedian 2.0x 1.5xmedian 2.0x
PEG now vs peer median —median 0.43 0.65median 0.43 -4.05median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsALVOAMRXAMPH
Revenue -$131.44M $3.20B $745.79M
Gross profit -$270.71M $1.29B $349.09M
Operating income $142.52M $478.99M $139.74M
Net income $52.16M $175.49M $98.96M
Free cash flow -$122.64M $38.42M $139.02M
R&D $92.89M $180.59M $92.29M
EPS (diluted) $-0.11 $0.40 $2.28
Cash & equivalents $172.36M $157.40M $204.59M
Total debt $1.40B $3.12B $613.00M
Shares (diluted) 291.34M 335.73M 43.38M
Enterprise value $729.59M $6.39B $181.00M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricALVOAMRXAMPH
P/E -39.2x 53.8x 12.6x
P/FCF -10.7x 193.9x 9.0x
P/Operating cash flow -22.5x 41.2x 7.1x
P/S -9.9x 2.3x 1.7x
P/B -4.6x 14.0x 1.5x
P/Tangible book -2.8x -7.3x 1.6x
EV/EBITDA 9.5x 15.1x 32.2x
EV/EBIT 17.8x 21.7x 11.7x
EV/Revenue -19.3x 3.3x 2.2x
EV/FCF -20.6x 271.0x 11.8x
EV/Operating cash flow -43.5x 57.6x 9.3x
PEG (3Y EPS CAGR) – 0.65 -4.05

Growth

14 metrics
MetricALVOAMRXAMPH
Revenue growth (1Y) -137.5% 8.9% 3.1%
Revenue CAGR (3Y) – 10.2% 7.4%
Gross profit growth (1Y) -383.2% 19.2% -2.2%
Gross profit CAGR (3Y) – 15.0% 2.3%
Operating income growth (1Y) 166.0% 33.8% -6.8%
Operating income CAGR (3Y) – 28.4% -8.2%
Net income growth (1Y) 122.5% 271.2% -11.3%
Net income CAGR (3Y) – 53.6% -9.9%
EPS growth (1Y) 87.7% 2,085% -2.6%
EPS CAGR (3Y) – 83.1% -3.1%
Operating cash flow growth (1Y) 75.4% -44.9% 15.1%
Operating cash flow CAGR (3Y) – -1.1% 0.1%
Free cash flow growth (1Y) 52.6% -84.6% 22.7%
Free cash flow CAGR (3Y) – -35.0% -0.2%

Profitability

14 metrics
MetricALVOAMRXAMPH
Gross margin – 40.2% 46.8%
EBITDA margin – 21.5% 6.8%
Operating margin – 15.0% 18.7%
Pretax margin – 6.9% 17.4%
Net margin – 4.2% 13.3%
FCF margin – 1.2% 18.6%
Operating cash flow margin 44.3% 5.7% 23.5%
Return on equity – 74.3% 12.5%
Return on assets -1.9% 4.6% 5.7%
Return on invested capital 8.2% 14.3% 7.6%
Return on capital employed 11.0% 14.1% 9.0%
Asset turnover -0.1x 0.7x 0.4x
Cash conversion (OCF / net income) -1.1x 1.0x 1.8x
Stock comp / revenue -5.0% 1.2% 4.0%

Financial Health

11 metrics
MetricALVOAMRXAMPH
Debt / assets 86.4% 59.2% 35.8%
Debt / equity -4.9x 5.9x 0.8x
Net debt / EBITDA 4.6x 4.3x 7.5x
Debt / FCF -11.4x 81.2x 4.4x
Liabilities / assets 117.6% 89.9% 52.4%
Equity / assets -17.6% 10.1% 47.6%
Interest coverage 44.7x – 5.3x
Current ratio 1.9x 1.9x 3.3x
Quick ratio 1.4x 1.1x 2.3x
Cash ratio 0.6x 0.1x 1.3x
Altman Z-score -1.39 1.96 2.44

Shareholder Returns

7 metrics
MetricALVOAMRXAMPH
Dividend yield – – –
Net buyback yield – 0.0% 7.2%
Shareholder yield – 0.0% 7.2%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusALVOAMRXAMPH
Forward P/E – 21.4xFY2026 8.8xFY2026
EPS, next fiscal year $-0.04FY2026 $1.00FY2026 $3.34FY2026
EPS growth, next FY – +20.5%FY2026 +2.8%FY2026
EPS growth, the year after – +26.0% +6.9%
Revenue, next fiscal year $555.88MFY2026 $3.30BFY2026 $802.03MFY2026
Revenue growth, next FY -6.3%FY2026 +9.1%FY2026 +11.4%FY2026
Revenue growth, the year after +23.4% +12.6% -5.7%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersALVOAMRXAMPH
Held by institutions 14.7% 51.0% 64.8%
Institutions holding 72 310 209
Change in shares held, QoQ +152.4% +1.3% -11.7%
Institutions buying 44 182 96
Institutions selling 17 86 74
Buyers to sellers 2.59 2.12 1.30

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ALVOAMRXAMPH
ALVO 1.00 0.19 0.14
AMRX 0.19 1.00 0.45
AMPH 0.14 0.45 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ALVO, AMRX and AMPH?

Amneal Pharmaceuticals (AMRX) is the largest by market capitalisation: Alvotech (ALVO) $1.28B, Amneal Pharmaceuticals (AMRX) $7.15B, Amphastar Pharmaceuticals (AMPH) $1.28B.

Which stock is cheaper, ALVO, AMRX and AMPH?

Amphastar Pharmaceuticals (AMPH) trades on the lowest price-to-earnings ratio (Alvotech (ALVO) -41.3x, Amneal Pharmaceuticals (AMRX) 53.6x, Amphastar Pharmaceuticals (AMPH) 12.9x). On next year's consensus earnings, Amphastar Pharmaceuticals (AMPH) is cheapest (Amneal Pharmaceuticals (AMRX) 21.4x, Amphastar Pharmaceuticals (AMPH) 8.8x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Amneal Pharmaceuticals (AMRX) grew revenue fastest over the trailing twelve months: Alvotech (ALVO) -137.5%, Amneal Pharmaceuticals (AMRX) +8.9%, Amphastar Pharmaceuticals (AMPH) +3.1%.

Which company is more profitable?

Amphastar Pharmaceuticals (AMPH) has the highest net margin (Amneal Pharmaceuticals (AMRX) 4.2%, Amphastar Pharmaceuticals (AMPH) 13.3%). On return on invested capital, Amneal Pharmaceuticals (AMRX) leads (Alvotech (ALVO) 8.2%, Amneal Pharmaceuticals (AMRX) 14.3%, Amphastar Pharmaceuticals (AMPH) 7.6%).

Which stock has performed better?

Over the past year Amneal Pharmaceuticals (AMRX) returned the most: Alvotech (ALVO) -24.1%, Amneal Pharmaceuticals (AMRX) +85.6%, Amphastar Pharmaceuticals (AMPH) +11.4%. Over five years, Amneal Pharmaceuticals (AMRX) compounded fastest (Alvotech (ALVO) -15.8%/yr, Amneal Pharmaceuticals (AMRX) +32.7%/yr, Amphastar Pharmaceuticals (AMPH) +6.6%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Amneal Pharmaceuticals (AMRX) has been the steadiest (Alvotech (ALVO) 70.5%, Amneal Pharmaceuticals (AMRX) 34.3%, Amphastar Pharmaceuticals (AMPH) 53.3%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ALVO, AMRX and AMPH?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Amneal Pharmaceuticals (AMRX) leads on 7. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.